Brief Monitoring Patient Access to Facility-Based Opioid Use Disorder Treatment in New Jersey
Lisa Clemans-Cope, Marni Epstein, Emma Winiski
Display Date
Download Report
(692.94 KB)

Expanding access to effective treatment for opioid use disorder (OUD) is essential to staunching the opioid epidemic. This brief is one of the first studies to assess patient access to treatment services for OUD at facilities that offer OUD pharmacotherapy across New Jersey. We conducted phone surveys in 2018 with substance use treatment facilities in New Jersey. This brief presents data about specific treatment service availability, wait times, and Medicaid coverage of treatment, including region- and county-specific data to assess the supply and demand of various treatment options throughout New Jersey. We estimate that only 49 percent of substance use treatment facilities offered any form of OUD pharmacotherapy—buprenorphine, methadone, or naltrexone. Overall, patients had a median wait time of two days for both regular and intensive outpatient services, but wait times varied widely across both county and service type.

Research Areas Health and health care
Tags Health equity Medicaid and the Children’s Health Insurance Program  Private insurance Community-based care
Policy Centers Health Policy Center